Cargando…

Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis

BACKGROUND: The weight loss benefit of semaglutide in patients with diabetes is well-documented, but its clinical utility in treating obesity among patients without diabetes is less described. We therefore assessed the efficacy and safety of subcutaneous semaglutide as treatment for obesity in patie...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tan, Hanna Clementine, Dampil, Oliver Allan, Marquez, Maricar Mae
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Journal of the ASEAN Federation of Endocrine Societies 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758543/ https://www.ncbi.nlm.nih.gov/pubmed/36578889 http://dx.doi.org/10.15605/jafes.037.02.14

Ejemplares similares

MON-602 The Efficacy and Safety of Sodium-Glucose Transport Protein 2 (SGLT-2) Inhibitors for Weight Loss Among Individuals Without Diabetes: A Systematic Review and Meta-Analysis
por: Cabrera, Carmen Carina, et al.
Publicado: (2020)

Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials
por: Gao, Xueqin, et al.
Publicado: (2022)

Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review
por: Xie, Zeyu, et al.
Publicado: (2022)

A Review on the Efficacy and Safety of Oral Semaglutide
por: Niman, Stephanie, et al.
Publicado: (2021)

Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity
por: John, Linu M, et al.
Publicado: (2021)

Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity
por: Ghusn, Wissam, et al.
Publicado: (2022)

Efficacy of Repetitive Transcranial Magnetic Stimulation (rTMS)in Inducing Weight Loss among Obese Filipino Patients:A Randomized Controlled Trial
por: Encarnacion, Margaret, et al.
Publicado: (2020)

Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials
por: Zhang, Rui, et al.
Publicado: (2023)

Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Wegovy (semaglutide): a new weight loss drug for chronic weight management
por: Singh, Gurdeep, et al.
Publicado: (2022)

Corrigendum: Safety of Semaglutide
por: Smits, Mark M., et al.
Publicado: (2021)

Comparison of the Efficacy of Levothyroxine Suppression Dose Computed Based on Actual Body Weight vs. Lean Body Mass among Differentiated Thyroid Cancer Patients: A Randomized Controlled Trial
por: Lu, Johanna, et al.
Publicado: (2019)

Efficacy and safety of semaglutide in non-alcoholic fatty liver disease
por: Zhu, Kai, et al.
Publicado: (2023)

Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists
por: Okamoto, Aki, et al.
Publicado: (2021)

Semaglutide in Obesity: Unmet Needs in Men
por: Jensterle, Mojca, et al.
Publicado: (2023)

Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1)
por: Wilding, John P H, et al.
Publicado: (2021)

Efficacy and Safety of Subcutaneous and Oral Semaglutide Administration in Patients With Type 2 Diabetes: A Meta-Analysis
por: Zhong, Ping, et al.
Publicado: (2021)

Comparison of the Harris-Benedict Equation, Bioelectrical Impedance Analysis, and Indirect Calorimetry for Measurement of Basal Metabolic Rate among Adult Obese Filipino Patients with Prediabetes or Type 2 Diabetes Mellitus
por: Luy, Sybil Claudine, et al.
Publicado: (2018)

Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs
por: Carmina, Enrico, et al.
Publicado: (2023)

Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review
por: Deng, You, et al.
Publicado: (2022)

Safety and Efficacy of Glucomannan for Weight Loss in Overweight and Moderately Obese Adults
por: Keithley, Joyce K., et al.
Publicado: (2013)

The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis
por: Lautenbach, Anne, et al.
Publicado: (2022)

Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)
por: Rubino, Domenica M, et al.
Publicado: (2021)

Insulin Resistance and β-Cell Function of Lean versus Overweight or Obese Filipino Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Bautista, Francesca Paula, et al.
Publicado: (2019)

Semaglutide for the treatment of overweight and obesity: A review
por: Bergmann, Natasha Chidekel, et al.
Publicado: (2022)

SAT-102 Self-efficacy As A Predictor Of Weight Loss In Veterans With Obesity Participating In Medical Weight Management.
por: Parziale, Andrew, et al.
Publicado: (2019)

Once-weekly 2.4 mg Semaglutide for Weight Management in Obesity: A Game Changer?
por: Colin, Ides M, et al.
Publicado: (2022)

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss
por: Wharton, Sean, et al.
Publicado: (2021)

Efficacy of Semaglutide in Treating Obesity: A Systematic Review of Randomized Controlled Trials (RCTs)
por: Anam, Mahvish, et al.
Publicado: (2022)

Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2)
por: Davies, Melanie, et al.
Publicado: (2021)

Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice
por: Pérez-Belmonte, Luis M., et al.
Publicado: (2022)

Efficacy and safety of once-weekly semaglutide for the treatment of type 2 diabetes: Protocol for a systematic review and meta-analysis
por: Shi, Fang-Hong, et al.
Publicado: (2018)

Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis
por: Alsugair, Hassan A., et al.
Publicado: (2021)

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme
por: Aroda, Vanita R., et al.
Publicado: (2022)

Efficacy, safety, and patient satisfaction with oral semaglutide: first single-centre clinical experience
por: Janić, Miodrag, et al.
Publicado: (2023)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
por: Meier, Juris J.
Publicado: (2021)

Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4)
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
por: Quddos, Fatima, et al.
Publicado: (2023)

The efficacy and safety of oral semaglutide for glycaemic management in adults with type 2 diabetes compared to subcutaneous semaglutide, placebo, and other GLP-1 RA comparators: A systematic review and network meta-analysis
por: Alhindi, Yousef, et al.
Publicado: (2022)

The Effect of Semaglutide on Blood Pressure in Patients without Diabetes: A Systematic Review and Meta-Analysis
por: Kennedy, Cormac, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7f98flqqllbc6f7esrj5fbgdrj